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Abstract Secretion of cytokines by monocytes has been im­
plicated in the pathogenesis of dialysis-related morbidity. Cy­
tokine generation is presumed to take place in two steps: 
induction of mRNA transcription for cytokines by C5a and 
direct membrane contact, followed by lipopolysaccharide 
(LPS)-induced translation of mRNA (priming/second signal 
theory, Kidney Int 37: 85-93, 1990). However, the in vitro 
conditions on which this theory was based differed markedly 
from clinical dialysis. To test this postulate for routine hemo­
dialysis, 13 patients were studied cross-over with high-flux 
cuprammonium (CU), cellulose triacetate (CTA), and polysul- 
fon dialyzers, using standard bicarbonate dialysate, as well as 
CTÀ with filtered dialysate (fCTA). Besides leukocytes, C3a, 
C5a, and limulus amebocyte lysate reactivity, tumor necrosis 
factor (TNF)-a, interleukin (IL)-lß, IL-6 , IL-1RA, soluble 
TNF receptors, and IL -lß  mRNA were assessed. Only during 
dialysis with CU did C5a increase significantly (561 to 8185 
ng/ml, P  <  0.001). Endotoxin content of standard bicarbonate
was higher than filtered dialysate (median, 24.3 and < 5  pg/ml 
respectively, P =  0.002), whereas limulus amebocyte lysate 
reactivity was not detected in the blood, except in the case of 
CU. TNF-ce levels were elevated before, and remained stable 
during, dialysis, independent of the modality used. IL-lj3, IL-6, 
and mRNA coding for IL - lß  could not be demonstrated. 
IL-1RA and soluble TNF receptors (p55/p75) were markedly 
elevated compared with normal control subjects, but showed 
no differences between fCTA and CTA, To summarize, no 
evidence was found for production and release of cytokines by 
monocytes during clinical high-flux bicarbonate hemodialysis, 
neither with complement-activating membranes nor with un­
filtered dialysate. Therefore, this study sheds some doubt on 
the relevance of the “priming/second signal” theory for clinical 
practice. The data presented suggest that reluctance to pre­
scribe the use of high-flux dialyzers, as advocated in many 
reports, may not be warranted. (J Am Soc Nephrol 8: 1745- 
1754, 1997)
Numerous reports have been published about the unfavorable 
interactions between peripheral blood and dialyzer membrane 
in hemodialysis (HD) patients (1,2). One of the first phenom­
ena described was a transient decline in the number of circu­
lating neutrophils (3,4), related to alternative pathway comple­
ment activation (5,6). The complex of HD-induced acute and 
chronic side effects has been termed bioincompatibility (7). 
More recently, evidence has been obtained that proinflamma- 
tory cytokines are involved in this process (8-10). The close 
similarities between their biological effects and the clinical 
symptoms in HD patients (11,12) have led to the proposal of 
the interleukin hypothesis (13). This theory suggested that the 
release of proinflammatory cytokines acts as an underlying 
pathophysiologic event in HD-related acute-phase responses, 
such as fever and hypotension. A potential role of cytokines
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(14) in chronic dialysis-related morbidity, such as amyloidosis 
and muscle wasting (15), was also suggested.
However, both the nature of and the factors responsible for 
the activation of peripheral blood mononuclear cells (PBMC)
(15) are controversial issues. Besides a normal basal activation 
state (16-18), an increase (19,20), as well as a decline (21,22), 
have been described. Moreover, both an elevated response to 
exogenous stimuli (21-23) and a decrease have been observed 
(24). The discrepant findings may be due to the various test 
systems used (25). For the activation of PBMC and subsequent 
cytokine release, various factors have been implicated, such as 
complement activation (26-29), acetate dialysate (30), direct 
cell-dialyzer interaction (31), and backtransport of bacterial- 
derived material from the dialysate to the blood compartment
(32).
In 1990, an attractive hypothesis was presented defining the 
nature of HD-induced PBMC cytokine generation more pre­
cisely (28): Primarily complement activation, but also direct 
PBMC adherence to the dialyzer, serves as a priming event and 
results in the transcription of mRNA coding for the cytokines 
interleukin (IL )-lß  and tumor necrosis factor (TNF)-a. There­
after, a second signal is required, such as backtransport of
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bacterial-derived substances, resulting in mRNA translation 
and subsequent production and release of cytokines.
However, although fascinating, the above-mentioned theory 
has been based primarily on data obtained under highly un- 
physiological conditions that may have confounded the out­
come for several reasons. First, the in vitro dialysis circuit was 
perfused for 2 h with 100 ml of saline, supplemented with 80 
ml of donor blood. Obviously, the repeated exposure of a small 
amount of diluted test blood may amplify cellular activation, at 
least in comparison with clinical HD. Second, donor blood was 
obtained from healthy human volunteers, most likely exhibit­
ing normal immune responses, in contrast to uremic patients 
(8). Third, in clinical HD the entire immune system will be 
involved in the inflammatory response caused by HD. Hence, 
in vitro both the participation of neutralizing factors, such as 
lipopoly saccharide (LPS)-binding proteins (33) and inhibitors 
of cytokines (34), and the influx of new cells originating from 
the marginating pool (35), will markedly differ from the clin­
ical situation. Fourth, PBMC were incubated with LPS doses, 
up to 1000-fold larger than those found in clinical HD (36,37). 
Fifth, Escherichia coli> a notably uncommon bacterial contam­
inant of HD systems, was used for the preparation of LPS (37). 
Finally, acetate-containing dialysate was used, which is known 
to induce PBMC activation (30), Hence, the question arises 
whether conclusions, based on results obtained from in vitro 
recirculation systems, are relevant for clinical bicarbonate di­
alysis.
In the present study, 13 stable patients underwent bicarbon­
ate HD cross-over on three dialyzers (cuprammonium [CU], 
cellulose triacetate [CTA], and polysulfon [PS]), differing in 
membrane material, degree of complement activation, pore- 
size, and absorptive characteristics (38). In the case of CTA, 
standard as well as filtered dialysate was used. The objective of 
our study was twofold: (7) to assess the production and release 
of cytokines by PBMC in routine bicarbonate HD and, more 
specifically, the impact of complement activation, membrane 
material, and contamination of the dialysate on this process; 
and (2) to evaluate the validity and relevance of the “priming/ 
second signal” theory for clinical HD.
Materials and Methods
Patients
Thirteen stable patients (three women and 10 men undergoing HD 
for at least 5 mo [median, 35 mo; range, 6 to 224] and with a median 
age of 68 yr [range, 27 to 88 yr]) participated in the study after giving 
informed consent. Exclusion criteria were comorbidity (malignancy, 
autoimmune disease) or medication that might interfere with the 
immune system (nonsteroidal anti-inflammatory drugs, cytostatics, 
prednisone).
Dialyzers
Dialyzers were selected according to the following criteria:
Complement Activation. As outlined in the introductory re­
marks, dialyzers were selected first on the basis of their known 
complement-activating properties. Therefore, low- (PS), low-average 
(CTA), and high- (CU) complement-activating membranes were cho­
sen to offer different levels of complement products as priming event 
(Table 1).
Membrane Material. Direct contact between blood and dialyzer 
might stimulate PBMC to cytokine mRNA transcription, depending 
on the type of membrane used (28). Furthermore, dialyzers differ in 
their ability to adsorb proteins and pyrogens onto their membrane 
surface (39). CU and PS appeal' to behave quite opposite in this 
respect. Elegant studies showed that radioactive LPS was eluted in 
larger quantities from PS than from CU (40). Other investigators 
demonstrated that plasma coating significantly reduced the pyrogen 
permeability in the case of PS, but not in the case of CU (41). Hence, 
based on these criteria, one synthetic (PS) and two cellulosic (CU, 
CTA) membranes were selected.
Pore Size. According to the priming/second signal theory, the 
transfer of cytokine-inducing substances across the membrane offers 
the second signal for primed PBMC. The molecular weight of LPS is 
approximately 100 kD, and that of exotoxins 25 to 78 kD (37,42). 
Because the molecular size exclusion of dialysis membranes is below 
these molecular weights (PS and CTA: ±30 kD; CU: ±27 kD; 
reference 43), only fragments of these substances are likely to per­
meate the membrane. Hence, dialyzers with large pore sizes, and 
consequently high ultrafiltration (UF) factors, were selected (PS: 40; 
CTA: 35 ml/mmHg per h). In the case of CU, the highest UF factor 
available was 20 ml/mmHg per h.
Dialyzers with Filtered Dialysate. To avoid the second signal as 
much as possible, one additional HD session was performed with 
dialysate that had been passed through an endotoxin filter (41). On the 
basis of the combination of modest complement activation (4) and 
potential backtransport (high UF factor), CTA dialyzers were selected 
for this extra experimental session (filtered CTA [fCTA]).
Study Design
A diagram of the dialysis modalities used is depicted in Figure 1. 
All patients were dialyzed for 3 wk with each dialyzer in a cross-over 
study design. In each third week, blood samples were collected during 
a single HD session. In the case of CTA dialysis, blood samples were 
collected twice in 1 wk (once with standard and once with filtered 
dialysate).
Samples drawn from the afferent line before dialysis and from the 
efferent line several times afterward (see following sections) were 
analyzed for leukocyte count, C3a and C5a, limulus amebocyte lysate 
(LAL) reactivity, IL-ljS, IL-6, TNF-a, IL-RA, soluble TNF receptors 
(sTNFR), and mRNA coding for IL-lß. Dialysate samples taken at 
180 min afterward were cultured for bacterial growth and analyzed for 
LAL reactivity.
Table L  Dialyzer characteristics51
Dialyzer CT 150 G AM-UP-75 F 60S
Material Cellulose Cellulose Polysulfon
triacetate
Surface area 1.5 m2 1.5 m2 1.3 m2
Sterilization Gamma Gamma Steam
Structure Capillary Capillary Capillary
UF factor 35 20 40
(ml/mmHg per h)
a UF, ultrafiltration. CT 150 G was from Baxter (Osaka, Japan), 
AM-UP-75 was from Asahi (Tokyo, Japan), and F 60 S was from 
Fresenius (Bad Homburg, Germany).
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Figure 1. Study design. Thirteen patients were dialyzed according to the four modalities, as shown in the diagram. Selection of dialyzers was 
based principally on their complement-activating properties (priming event) and potential transmembrane permeation of cytokine-inducing 
substances (second signal).
Dialysis Procedure and Materials
Before the study, all patients underwent dialysis with low-flux PS. 
All dialyzers (CTA: CT 150 G, Baxter, Osaka, Japan; PS: F 60 S, 
Fresenius, Bad Homburg, Germany; CU: AM-UP-75, Asahi, Tokyo, 
Japan) were comparable in surface area, in vitro performance, and 
sterilization procedure (ethylene oxide-free). The UF coefficient dif­
fered slightly between the devices (Table 1).
Only first-use dialyzers, prerinsed with 1000 ml of NaCl 0.9% 
containing 5000 IU of heparin, were used. For dialysate preparation, 
tap water, purified by reversed osmosis, was used for dilution of a 
concentrated bicarbonate solution (138 mM Na+, 2 mM K‘h, 1.75 mM 
Ca2+, 0.5 mM Mg2+, 109.5 mM Cl", 3 mM CH3COO“ , and 32 mM 
HCO j^”). Dialysate flow was 500 ml/min. Filtered dialysate was ob­
tained by the interposition of a PS filter (SPS 600, Fresenius) (44).
The dialysis sessions lasted 3 to 4 h, depending on the previous 
prescription of the patients. All assessments were performed within 
the first 3 h, during which blood flow and UF rates were kept constant, 
according to the individual needs of the patients (blood flow, 200 to 
250 ml/min; UF rate, 300 to 1000 ml/h). Anticoagulation was 
achieved by heparin with a priming dose of 1250 to 5000 IU and 250 
to 1500 IU/h continuously. Individual conditions (blood flow, heparin 
dose, and UF) were maintained stable throughout the study period.
Analytical Methods
Leukocytes. Leukocyte counts and differentiation were deter­
mined from samples drawn in tripotas sium ethylenediamine tetra- 
acetic acid (EDTA) before dialysis (tO) and at 7.5 (t7.5), 15 (tl5), 30 
(t30), and 180 (tl80) min afterward, using a Sysmex NE-8000 cell 
analyzer (TOA Medical Electronics, Kobe, Japan).
Complement Activation Products. On the basis of a pilot study, 
sample times for complement determination were fixed at tO, tl5, and 
tl 80. Samples were collected in tubes containing tripotassium EDTA, 
kept on ice, and centrifuged immediately at 4°C for 10 min at 1500 g. 
The plasma was then stored at —70°C until required for testing. One 
hundred microliters of plasma were treated with 50 jjl 1 of 30% poly­
ethylene glycol 6000 (BDH Poole, United Kingdom) in phosphate- 
buffered saline containing 10 mM EDTA, pH 7.2 to 7.5 (45). After 
centrifugation, the supernatant was collected for determination of C3a 
and C5a with an inhibition RIA, as has been described for the 
detection of IL-2 (46). In short, a monospecific polyclonal rabbit 
antibody against C3a or C5a was incubated overnight with the test 
sample. After that, iodinated C3a or iodinated recombinant C5a was 
added, and a second overnight incubation was performed. Complexed 
labeled C3a or C5a was precipitated with goat anti-rabbit antiserum in 
the presence of 5.6% polyethylene glycol 6000. Inhibition of the 
precipitation of hot C3a or C5a indicated the presence of these 
substances. The assays were calibrated using standard curves obtained 
with recombinant C5a (Sigma, St. Louis, MO) or purified C3a. The 
range of detection was 62 to 1000 ng/ml for C3a and 781 to 12,500 
pg/ml for C5a. The average intra-assay coefficient of variance for C3a 
and C5a was 2 to 4% and 2 to 6%, respectively.
Endotoxin Assay. Blood samples for endotoxin determinations 
were collected at tO and tl80 in heparinized and pyrogen-free mate­
rials (Monovette®, Sarstedt, Nümbrecht, Gennany); dialysate samples 
were collected only at 1180. The blood samples were centrifuged at 
190 g for 10 min at 4°C to obtain platelet-rich plasma (PRP). All 
samples were stored at —20°C until determination.
Endotoxin activity was quantified by a kinetic chromogenic
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method based on LAL by measurement of the activated enzyme by the 
sensitive chromogenic substrate S 2422 (Kinetic-QCL, Boehringer 
Ingelheim Bioproducts, Verviers, Belgium), Software was modified to 
allow detection of 1 pg of LPS per milliliter of PRP.
All determinations were performed in duplicate. After 1:10 dilu­
tion, PRP was heated for 10 min at 75 °C (47,48). Standard series of 
purified Escherichia coli 055:B5 endotoxin (Boehringer Ingelheim 
Bioproducts) were made in PRP obtained from a healthy volunteer 
and endotoxin-free water (LAL-reagent water). All standard series 
showed linearity from 1 to 25 pg of LPS per milliliter of PRP. 
Inhibition and interference testing was performed on each sample by 
an endotoxin spike (Escherichia coli 055:B5 endotoxin, Boehringer 
Ingelheim Bioproducts) equal to 5 pg of LPS per milliliter of PRP. 
Recoveries of spikes between 50 and 150% were accepted.
Microbiological Evaluation of Dialysate. Dialysate samples 
were drawn in sterile tubes. Total plate counts were performed on 
glucose yeast extract agar (Merck, Darmstadt, Germany; Oxoid, Bas­
ingstoke, United Kingdom) and on Columbia agar (Oxoid) with sheep 
red blood cells after 48 h of incubation at 37°C. Identification of 
micro-organisms was achieved using Analytical Profile Index identi­
fication (Analytical Profile Index system S.A., Montalieu-Verceu, 
France).
Cytokines. The cytokines IL» lß  and IL-6 were determined at tO, 
t30, and tl80, and TNF-a at tO and t l 80, in serum by sandwich-type 
enzyme immunoassays, according to the manufacturers’ procedures 
(IL-lß  and TNF-a [Immunotech, Marseille, France], and IL-6 [Cen­
tral Laboratory of the Netherlands Red Cross Blood Transfusion 
Service, Amsterdam, The Netherlands] (49). After centrifugation (10 
min, 1500 the serum samples were stored immediately at -70°C 
until required for testing. All determinations were performed in un­
diluted samples and in duplicate. Lower limits of detection for IL-lß, 
TNF-a, and IL-6 were 5, 10, and 4 pg/ml, respectively. The average 
intra-assay coefficient of variation was 5.1% for IL-lß, 10% for 
TNF-a, and 7.6% for IL-6. Data at t!80 were corrected for changes in 
hematocrit (Ht): corrected value,, 80 = (Httû/Htt{80) X valuetls0. Se­
rum samples of septic patients served as positive control subjects (n =
9, median [range]: IL-lß 5 (0 to 218) pg/ml; TNF-a: 9 (0 to 102) 
pg/ml; IL-6, 105 (3 to >750) pg/ml).
IL-1RA and sTNFR. IL-1RA was measured at tO and tl80 in
100 fxl of EDTA plasma with an RIA, using polyclonal rabbit anti­
bodies as described by Drenth et al (50). The lower detection limit of 
this assay was 80 pg/ml. Normal values, as measured in 97 healthy 
volunteers, were 156 ± 7 8  pg/ml. sTNFR were measured at tO and 
tl80, using an enzyme-linked immunobinding assay (Hoffmann-La 
Roche, Basel, Switzerland) (51). Normal values, as measured in 19 
healthy volunteers, were 1470 ± 190 pg/ml for sTNFR-p55 and 
2520 ±  660 pg/ml for sTNFR-p75. Data at tl80 were corrected for 
changes in Ht.
mRNA Coding for IL-lß. PBMC were isolated from EDTA 
blood samples by density gradient centrifugation on Ficoll-Paque 
(d = 1.077 g/cni3, Pharmacia, Uppsala, Sweden). Total cellular RNA 
from these cells was isolated with RNAzoi (Biotecx Laboratories, Ive 
Houston, TX), according to the procedure described by Chomczynski 
and Sacchi (52), and reverse-transcribed into cDNA by oligo~dT 
priming. Deoxyoligonucleotide primers were constructed from the 
published cDNA sequences of IL-lß (53) and ß-actin (54). The 
primers were synthesized on a DNA synthesizer (Cyclone Millipore, 
Bedford, MA) by the phosphoramadite method (55).
The amplification of cDNA by PCR was performed by a modified 
procedure of Saiki (56). Ten microliters of cDNA, 50 pmol of each 
primer, and 0.5 U of Taq DNA polymerase were added to a final 
volume of 100 ^1 (50 mM KC1, 10 mM Tris-HCl, pH 8.3, 2.0 mM
MgCl2, 2 mg/ml bovine serum albumin, and 0.25 mM of each dNTP). 
The mixture was heated to 95°C, 1.5 min at 55°C, and 1.0 min at 72°. 
After termination of the last cycle, the samples were chilled to 4°C 
Ten microliters of the amplified DNA was electrophoresed on 1% 
agarose gels and analyzed for the appearance of bands of 388 and 527 
bp for IL-lß and ß-actin, respectively.
Sta tistica l A na lyses
Data are expressed as mean ± SD, or median and range when 
appropriate. Analysis was performed with the Statistical Package for 
Social Sciences/PC-f software system, using multivariate ANOVA 
and paired t test. In the case of the dialysate data, a Kolmogorov- 
Smirnov test was performed. Differences are considered statistically 
significant at P <  0.05.
Results
L eukocytes
At tl5 , all three membranes (four modalities) showed a 
decrease in the number of white blood cells (WBC), but only 
significantly in the case of CU (Figure 2). Comparing CTA 
with CU, multivariate analysis with a difference contrast 
showed an interaction between membrane and time (Hotell­
ing’s T2 test: F  =  20.87; df (2,9); P  <  0.001). Univariate 
analysis revealed a significant effect of membrane; the WBC 
dip was more pronounced with CU than with CTA (F =  38.44;
df (12,1); P  <  0.001) or PS (F =  19.51; df (12,1); P =  0.001).
The effect of time will not be discussed.
As expected, the WBC decline was mainly due to a drop in 
the number of polymorphonuclear cells (CTA from 3.96 to 
2.97 X  109/L; PS from 4.14 to 3.72 X  109/L; CU from 3.76 to 
0.29 X  109/L).
C om plem ent
As shown in Figure 2, only in the case of CU was a 
significant increase in C5a observed. Multivariate analysis as 
described above showed an interaction between membrane and 
time (comparison between CTA and CU: Hotelling’s T2 test: 
F  =  26.45, df (1,11); P <  0.001), and further univariate
analysis revealed a highly significant membrane-dependent
effect on C5a levels (comparison between CTA and CU: F = 
45.40, df (12,1), P  <  0.001; likewise, between PS and CU: P <
0.001). No marked differences were observed between PS, 
CTA, and fCTA. With respect to C3a, results were comparable 
to C5a measurements (data not shown).
E ndotoxin  C ontent o f  D ia lysa te  and B lood  
Dialysate endotoxin content during HD with filtered and 
unfiltered dialysate is shown in Table 2. The difference be­
tween fCTA (filtered dialysate) and the average of the other 
treatment groups combined (standard dialysate) was highly 
significant (filtered, < 5  [< 5  to 14] pg/ml; standard, 24.3 [<5 
to 132] pg/ml; P  =  0.002). No marked variations were ob­
served between CTA, CU, and PS.
Neither during HD with fCTA nor during standard CTA and 
PS dialysis could endotoxins be detected in the blood (all 
samples, < 5  pg of LPS per milliliter of PRP), However, during 
CU dialysis, blood samples showed surprisingly high LAL
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Figure 2. (A) Leukocyte count (X109/L, mean and SD) during standard bicarbonate hemodialysis (HD) with cellulose triacetate (CTA), 
cuprammonium (CU), and polysulfon (PS) membranes, as well as with CTA and filtered bicarbonate dialysate (fCTA). HD with CU dialyzers 
induced a significant leukocyte dip after 15 min (*P <  0.001). (B) C5a levels (ng/ml) during HD with the above-mentioned modalities. Only 
HD with CU induced a significant increase in C5a after 15 min (**p <  0.001),
Table 2, Dialysate cultures and endotoxin Ievelsa
Characteristic Unfiltered Dialysateb(n = 39)
Filtered Dialysate 
(re = 13)
Dialysate culture 170(0 to 7500)c 30(0 to 40)c,d
(CFU/ml)
Gram stain (number)
positive
negative 15
positive and negative 5
none 19 13
Endotoxins (pg/ml) 24,3(<5 to 132) < 5(< 5  to 14.5)e
a CFU, colony-forming unit.
b Total of three modalities with unfiltered bicarbonate dialysate
(CTA, PS, CU). 
c Median (range).
d P < 0.001, filtered versus unfiltered dialysate. 
c P = 0.002, filtered versus unfiltered dialysate.
reactivity before and after HD (all samples, >250 pg of LPS 
per milliliter of PRP), which was markedly higher than con­
comitant dialysate levels (all samples, <36  pg/ml).
Dialysate Cultures
Results of the bacterial cultures from the dialysate are shown 
in  Table 2. Gram-positive organisms were cultured in five
cases, but only when gram-negative organisms were demon­
strated as well. When comparing fCTA with the total of non- 
filtered modalities, a highly significant difference was ob­
served (filtered dialysate fCTA, 30 [0 to 40] colony-forming 
units/ml; standard dialysate, 170 [0 to 7500] colony-forming 
units/ml; P  <  0.001).
TNF-a, IL-lß, and IL-6
Compared with healthy control subjects (n =  10; TNF-cn 
below the detection limit 10 pg/ml), mean T N F-a levels were 
moderately elevated (Figure 3) before and after 3 h of HD with 
all four dialysis modalities (tO: CTA 31.5, fCTA 22,1, PS 22.9, 
CU 20.5 pg/ml; tlSO; CTA 19.5, fCTA 14.0, CU 24.4, PS 17.1 
pg/ml). None of the four modalities showed marked differ­
ences between tO and tl80.
In the samples from the first six patients on CTA and PS 
dialysis (24 samples) and from all patients on CU dialysis (39 
determinations), IL-1/3 and IL -6 levels appeared to be below 
the detection limit (5 and 4 pg/ml, respectively) at all sampling 
times. Therefore, these cytokines were not determined in the 
remaining cases.
sTNFR and IL-1RA
Compared with healthy control subjects, both sTNFR-p55 
and sTNFR-p75 were markedly elevated in all four modalities
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Figure 3. Levels of tumor necrosis factor (TNF)-a (pg/ml) before (tO) and after ( tl80) dialysis with the four different modalities (Figure 1), 
Median values are indicated with a -h Serum levels were markedly elevated compared with normal control subjects. No significant changes 
were observed during HD or among the four modalities themselves.
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at all sampling times (mean p55: 23.9 ±  10.1 ng/ml; mean p75: IL-1 ß  (for a total of 52 determinations). Correct PBMC and
31.2 ±  7.4 ng/ml; control subjects: L5 ±  0.2 and 2.5 ±  0,7 RNA extractions were confirmed by agarose electrophoresis,
ng/ml, respectively, Figure 4). During HD with fCTA and showing 5S, 18S, and 28S mRNA. PCR accuracy was con-
CTA, a decrease in sTNFR-p55 was observed, whereas levels firmed by the assessment of /3-actin in all samples, 
remained stable during HD with CU and PS. The difference
between these two modalities and CTA or fCTA was signifi- Discussion
cant. Multivariate analysis, comparing CTA and CU, showed The present study was designed to elucidate the mechanism
an interaction between time and membrane (F =  9.82; df of cytokine generation by PBMC in routine bicarbonate HD, in
(1,11); P  =  0.01); further univariate analysis only showed a particular with respect to the priming/second signal theory, as 
significant effect of membrane (F =  18.24; df (1,11); P =  outlined in the introductory remarks (28). As for the priming 
0,001). In contrast, sTNFR-p75 increased during CU HD, event, dialyzers were used, differing both in membrane char- 
whereas it remained stable during HD with the other modalities acteristics and degree of complement activation. Potential 
(effect of membrane, CU versus CTA: F  = 12.06; df (1,9); backtransport of bacterial-derived substances in the dialysate, 
P <  0.01; CU versus fCTA and PS: P <  0,01). the so-called second signal ,  was facilitated by using only
Figure 4 shows the levels of IL-1RA at tO and tl 80 with the dialyzers with large pore sizes (57,58). In addition, the dialyz- 
four HD modalities, Although the measured quantities ap~ ers selected differed in their protein and pyrogen adsorptive 
peared to be approximately threefold higher compared with a capacities: CU low versus PS high (40,41). Finally, in one of 
group of healthy control subjects (mean CTA at tO: 490 ±  360 
pg/ml; mean control subjects: 156 ±  79 pg/ml), no marked 
differences were observed among the four modalities or be- (endotoxins), and/or non-LPS (exotoxins) (42), as much as
possible. According to a recent report, UF through pyrogen- 
adsorbing high-flux membranes such as PS improves the bac­
teriological quality by a factor of 102 to 103 (41).
Priming of PBMC was assessed by the analysis of mRNA 
coding for IL -lß . Sequelae of the so-called second-signal were
the experimental settings, the bicarbonate dialysate was filtered 
(fCTA), with the objective of excluding the second signal, LPS
tween the various sample times. Neither dialysate endotoxin 
levels nor dialysate cultures showed an influence on intradia- 
lytic changes in IL-1RA or sTNFR (p55 and p75) levels.
m R N A  coding f o r  I L - l ß
Neither mononuclear cells isolated after HD with LPS-free quantified by the assessment of blood cytokines IL -lß , IL-6 ,
dialysate (fCTA) nor samples isolated after the three other and TN F-a, as well as the neutralizing factors IL-IRA,
modes of HD (CU, CTA, and PS) showed mRNA coding for sTNFR-p55 (p55), and sTNFR-p75 (p75).
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A  dialysate contamination as assessed by cultures and LAL de­
terminations, was markedly reduced in the case of fCTA HD 
compared with the other modalities. In peripheral blood, all 
LAL determinations were negative, except in the case of CU, 
in which plasma levels were approximately 10-fold higher than 
concomitant dialysate levels before as well after HD. However, 
despite the high LAL reactivity in blood, neither mRNA for 
IL - lß  nor serum cytokines could be detected. Therefore, in our 
opinion, it is highly unlikely that the presence of LAL-positive 
material in blood was due to backtransport of bacterial-derived 
substances from the dialysate. The release of soluble, LAL- 
reactive membrane constituents, as has been described (59), 
seems a more plausible explanation for these findings.
With respect to TNF-a, average serum levels were moder­
ately elevated compared with healthy control subjects before, 
as well as after, HD, without notable differences between the 
four modalities. Hence, our data seem to be in line with reports 
indicating that plasma TN F-a levels are only slightly influ­
enced by HD (29,60) and are more or less similar to those 
found in continuous ambulatory peritoneal dialysis patients 
(34), although both an HD-induced increase (61) and decrease 
(34) have been reported as well. Nonetheless, our findings 
suggest that complement activation, membrane characteristics, 
and the quality of the dialysate did not influence the production 
of this cytokine (62).
Compared with healthy control subjects, all four modalities 
showed markedly elevated values of both sTNFR in HD pa­
tients, as has been described in uremic subjects (63). With 
respect to p55, HD with both CTA and fCTA showed a 
significant decline over time, whereas no notable variations 
were observed during HD with CU or PS. As for p75, dialysis 
with CU generated the highest levels, significantly different 
from fCTA, CTA, and PS. The above-mentioned differences, 
both for p55 and p75, persisted after correction for changes in 
hematocrit. On the basis of these data, a causative effect of 
complement activation and/or dialyzer characteristics, such as 
release of LAL-posit.ive membrane material in the case of CU 
(64), cannot be ruled out. Pooled data on CTA and CU mem­
branes also showed raised levels of sTNFR at the end of HD 
(34), which was attributed to acute shedding rather than to 
increased gene expression (65). Yet, our data indicate that the 
bacterial quality of the dialysate did not influence serum 
sTNFR levels.
With respect to IL - lß  and IL-6 , none of our experiments 
showed values higher than the detection limit, neither at the 
start nor at the end of HD. Hence, in our study, secretion was 
not influenced by complement activation, the type of mem­
brane, or the bacterial quality of the dialysate. In several recent 
studies, IL - lß  and IL-6 levels appeared similar in continuous 
ambulatory peritoneal dialysis patients and pre- and post-HD 
patients (34,60,66), suggesting that HD treatment itself does 
not stimulate PBMC to release notable amounts of these cyto­
kines, which is obviously in line with our findings.
In accordance with recent data (34), average IL-1RA levels 
A transient leukocyte drop, accompanied by marked com- appeared about three times as high as those from healthy 
plement activation (the proposed priming event), was demon- control subjects, before as well as after HD. No marked dif- 
strated only during CU dialysis. The second signal, bacterial ferences were observed between the various modalities. Again,
IL-1 RA (ng/ml)
0,8
0,6
0,4
0,2
0 -V.V.V.V.ViW.W 0 180
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Figure 4. Soluble TNF receptor (sTNFR) levels before (tO) and after 
(tl 80) dialysis with the four different modalities (Figure 1). Both 
sTNFR-p55 (ng/ml, Panel A) and sTNFR-p75 (ng/ml, Panel B) were 
markedly elevated compared with healthy control subjects (grey area). 
A significant decrease in p55 was noted during fCTA and CTA HD 
(*P <0.01), whereas p75 was significantly higher during CU dialysis 
compared with fCTA, CTA, and PS (**P < 0.01). As for interleu­
kin-1 receptor antagonist (IL-1RA) levels (ng/ml, Panel C), average 
se mm levels before HD were approximately threefold higher than in 
healthy control subjects (grey area). No marked changes were ob­
served during HD or among the four modalities themselves.
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these observations indicate that complement activation, mem­
brane characteristics, and the bacterial quality of the dialysate 
did not exert enhancing effects on serum IL-IRA levels. Re­
cent findings showed that IL -IRA even tended to decrease at 
the end of HD (34). These data seem even more striking, as 
endotoxin-stimulated PBMC from HD patients produce signif­
icantly more IL-1RA than IL -lß , indicating that IL-1RA might 
be a better indicator of cytokine-inducing stimuli than IL -lß  
(22,67). Finally, mRNA coding for IL -lß  could not be dem­
onstrated in any of the experiments performed, indicating that 
complement activation, different membrane characteristics, 
and type of dialysate used did not act as demonstrable priming 7, 
events.
Taken together, our data shed some doubt on the clinical 
relevance of the concept of a complement and/or membrane- 
induced transcriptional signal, followed by an endotoxin-in­
duced translational stimulus in routine bicarbonate HD. This
3. Kaplow LS, Goffinet JA: Profound neutropenia during the early 
phase of hemodialysis. JAMA 203: 133-135, 1968 
Grooteman MPC, Nubé MJ, van Limbeek J, van Houte AJ, Daha
skepticism is consistent with other observations. In an in vitro 
study, the transfer of cytokine-inducing substances was shown 
in the case of high-flux CTA and polyacrylonitrile membranes, 
but only after challenge doses of ±1000  pg/ml, which is 
approximately 30- to 50-fold larger than the unfiltered dialy­
sate used in our analysis (37). Others demonstrated that the 
presence of bacterial products in the dialysate, at the levels 
found in clinical conditions, did not influence cytokine profiles 
during in vitro HD with polyacrylonitrile and CU membranes 
(68).
In conclusion, neither transcription of mRNA coding for 
IL -lß  nor HD-induced release of IL -lß , IL-6, and TNF-a 
could be demonstrated in our study, despite considerable dif­
ferences in complement activation, membrane characteristics, 
and bacterial contamination of the dialysate between the four 
modalities tested. With respect to IL-1RA and sTNFR, com­
parable results were obtained, although an increase in sTNFR 
levels was observed during CU dialysis, possibly related to 
complement activation (34) and/or release of membrane-de­
rived LAL-positive material. Although the present data do not 
permit definite conclusions, our results shed some doubt on the 
relevance of the priming/second signal theory for clinical prac­
tice. Therefore, the reluctance to prescribe the use of high-flux 
dialyzers, as advocated by several authors (57,62,69,70), may 
not be warranted, at least as far as backtransport of cytokine- 
inducing substances is concerned.
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